About Us
Asia Air WatchLive PM2.5 Medical Alerts
Research Watch
•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs

The use of appropriate, inappropriate and no comparators in efficacy trials for European Medicines Agency-approved drugs 2011-2024: a retrospective cohort study.

Researchers

Camille E G Glaus, Cascal Herrle, Simon Hediger, Kerstin Noelle Vokinger

Abstract

New drugs should ideally have an added therapeutic benefit compared to existing treatments. In order to determine whether comparative evidence was available at approval, we analyzed the proportion of new drugs that were tested in efficacy trials based on appropriate, inappropriate and no comparators overall, over time and when differentiating between therapeutic areas. In this retrospective cohort study, we identified all new drugs approved by the EMA January 1, 2011 and December 31, 2024. The Federal Joint Committee determines the appropriate comparator of new drugs launched in Germany in publicly available assessment reports. We used these reports to determine whether the efficacy trials for each population of the drugs were conducted with the appropriate comparator. A drug indication was qualified as having compared with the appropriate comparator if at least one of its populations had an appropriate comparator. To analyze whether there was a statistically significant trend over time we estimated separate logistic regression models. We included 321 drug indications with 649 populations. 186/321 (58%) had at least one population tested with an appropriate comparator. Among the remaining indications, 87/321 (27%) had at least one population tested with an inappropriate comparator, and of those indications with at least one population not tested with an appropriate or inappropriate comparator, 48/321 (15%) had at least one population approved based on a single-arm trial. Differences occurred across therapeutic areas. Drug indications approved in 2023-2024 had 76% lower estimated odds of at least one population with an appropriate comparator compared with 2011-2012 (p-value: 0.01). By contrast, those approved in 2023-2024 had 7.5 times higher odds (p-value: 0.04) compared with 2011-2012 of being tested based on a single-arm trial. Less than two-thirds of drug indications were tested with an appropriate comparator as determined by the Federal Joint Committee, with a significant decrease over the past decade and a significant increase of single-arm trials. Other institutions may define the appropriate comparator differently. Future research is needed to assess the impact of the comparator choice on pricing and reimbursement. Swiss National Science Foundation.
Source: PubMed (PMID: 43036688)View Original on PubMed